G
Gergely Feher
Researcher at University of Pécs
Publications - 76
Citations - 1483
Gergely Feher is an academic researcher from University of Pécs. The author has contributed to research in topics: Hematocrit & Aspirin. The author has an hindex of 18, co-authored 67 publications receiving 1248 citations.
Papers
More filters
Journal ArticleDOI
Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease.
Klara Magyar,Robert Halmosi,Anita Pálfi,Gergely Feher,László Czopf,A. Fulop,I. Battyány,Balazs Sumegi,Kalman Toth,Eszter Szabados +9 more
TL;DR: The results show that resveratrol improved left ventricle diastolic function, endothelial function, lowered LDL-cholesterol level and protected against unfavourable hemorheological changes measured in patients with coronary artery disease (CAD).
Journal ArticleDOI
Diabetic neuropathies: diagnosis and management.
TL;DR: Intensive diabetes therapy, intensive multifactorial cardiovascular risk reduction and lifestyle intervention are recommended in patients with cardiovascular autonomic neuropathy.
Journal ArticleDOI
Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications.
TL;DR: Recent large scale randomized, controlled trials have consistently failed to demonstrate a benefit of personalised antiplatelet therapy based on platelet function testing.
Journal ArticleDOI
The genetics of antiplatelet drug resistance.
TL;DR: The antiplatelet mechanisms of aspirin and clopidogrel are reviewed and the possible role of different polymorphisms, which may affect the efficacy of antiplatelets therapy are reviewed.
Journal ArticleDOI
Clopidogrel resistance: Role of body mass and concomitant medications
Gergely Feher,Katalin Koltai,Balint Alkonyi,Elod Papp,Zsuzsa Keszthelyi,Gabor Kesmarky,Kalman Toth +6 more
TL;DR: The background of ineffective clopidogrel medication is complex and drug interactions may play a role on clopIDogrel bioavailability, on the other hand, the significant difference in BMI between the two examined groups suggests that clopidoogrel therapy should be weight-adjusted.